Nearly two thirds of US adults who start a GLP-1 for obesity have stopped taking it within a year.2
Please note: Halovance Bio operates in a stealth capacity.
Name
Corporate email
Nature of inquiryPlease selectStrategic partneringInvestment inquiriesGeneral inquiries
This reaches us directly. We use what you send only to respond. Privacy notice.